Home

Pathology

Alzheimer's Disease

Read time: 3 min

Congress highlights

Why does the cellular response to amyloid determine whether an individual develops Alzheimer’s disease?

What happens in the three decades between amyloid-beta (Aβ) deposition in the brain and the...

Alzheimer's Disease

Read time: 2 min

Congress highlights

Active immunotherapy targets early stage Alzheimer’s disease

Active immunotherapies have been designed to activate an immune response in the human body of...

Alzheimer's Disease

Read time: 3 min

Congress highlights

Initial promise of immunotherapeutics targeting amyloid-β strengthens the possibility of early intervention in Alzheimer’s disease

Clinical studies of immunotherapies show initial promise for early intervention in Alzheimer’...

Alzheimer's Disease

Read time: 3 min

Congress highlights

The many faces of tau offer multiple targets for intervention in Alzheimer’s disease

Tau is a complex, multifaceted target, implicated in many mechanisms involved in the pathology of...

Read time: 4 min

Congress highlights

Psychiatry’s white whale? The search for biomarkers for schizophrenia

Biomarkers are available and used effectively in other disorders– notably some of the cancers...

Parkinson's Disease

Read time: 4 min

Congress highlights

Non-motor symptoms – influencing ‘ON’ and ‘OFF’ in Parkinson’s disease

A broad spectrum of non-motor symptoms is highly prevalent in Parkinson’s disease (PD) which...

Read time: 3 min

Data drives better categorization of patients

Subtypes of Parkinson’s Disease patients with different risks of progression – and...

Read time: 4 min

Neuronal vulnerability, not being neighbors, underlies synuclein spread

Post mortem evidence and connectome mapping show that the distribution of Lewy pathology does not...

Alzheimer's Disease

Read time: 3 min

How beneficial is cholinesterase inhibition and for whom?

New evidence suggests that cholinesterase inhibition in prodromal Alzheimer’s disease (AD)...

Alzheimer's Disease

Read time: 4 min

Unpicking Alzheimer disease and depression

In this symposium four speakers discussed different approaches to investigating the intersection...

Read time: 6 min

New understanding of the gut microbiome may be the key to many diseases and pave the way for new therapies

The role of the gut microbiome in a range of psychiatric disorders, including depression and...

Read time: 4 min

Congress highlights

Mutual benefits: Public–Private Partnerships in CNS Research

Public–Private Partnerships are being developed worldwide to facilitate collaboration between...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country